Sampo plc
10.3.2021 08:04:52 CET | Globenewswire | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 10 March 2021 at 9:00 am
Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.)
Sampo plc (business code 0142213-3) has received a disclosure under Chapter 9, Section 5 of the Securities Markets Act, according to which the total number of Sampo A shares (ISIN: FI009003305) owned directly, indirectly or through financial instruments by BlackRock, Inc. (USA tax ID 32-0174421) and its funds on 8 March 2021 increased above 5 per cent. Also, the disclosure obligation arose due to voting rights attached to shares for BlackRock, Inc. increased above 5 per cent.
Sampo's share capital comprises 555,351,850 shares, of which 554,151,850 are A shares and 1,200,000 are B shares. Each A share entitles its holder to one (1) vote and each B share to five (5) votes. Thus, the total number of votes is 560,151,850.
Total positions of BlackRock, Inc and its funds subject to the notification:
| % of shares and voting rights (total of A) | % of shares and voting rights through financial instruments (total of B) | Total of both in % (A+B) | |
| Resulting situation on the date on which threshold was crossed or reached | 5.00% shares 4.96% voting rights | 0.11% shares 0.11% voting rights | 5.12% shares 5.07% voting rights |
| Positions of previous notification (if applicable) | Below 5% shares Below 5% voting rights | Below 5% shares Below 5% voting rights | Below 5% shares Below 5% voting rights |
Notified details of the resulting situation on the date on which the threshold was crossed:
A: Shares and voting rights:
| Class/type of shares ISIN code | Number of shares and voting rights | % of shares and voting rights | ||
| Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
| FI0009003305 | 27,782,299 shares 27,782,299 voting rights | 5.00% shares 4.96% voting rights | ||
| SUBTOTAL A | 27,782,299 shares 27,782,299 voting rights | 5.00% shares 4.96% voting rights | ||
B: Financial instruments according to SMA 9:6a:
| Type of financial instrument | Expiration date | Exercise/ Conversion Period | Physical or cash settlement | Number of shares and voting rights | % of shares and voting rights |
| American Depository Receipt (US79588J1025) | N/A | N/A | Physical | 263,012 shares 263,012 voting rights | 0.05% shares 0.05% voting rights |
| Securities Lent | N/A | N/A | Physical | 81,876 shares 81,876 voting rights | 0.01% shares 0.01% voting rights |
| CFD | N/A | N/A | Cash | 281,208 shares 281,208 voting rights | 0.05% shares 0.05% voting rights |
| SUBTOTAL B | 626,096 shares 626,096 voting rights | 0.11% shares 0.11% voting rights |
SAMPO PLC
Jarmo Salonen
Head of Investor Relations and Group Communications
tel. +358 10 516 0030
Distribution:
Nasdaq Helsinki
London stock exchange
The principal media
Financial Supervisory Authority
www.sampo.com
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
KAYTUS SYSTEMS PTE. LTD.29.9.2026 03:30:22 CEST | Press release
KAYTUS KR2166V3 Accelerates AIHPC Data Processing at Petabyte Scale
Evosep29.9.2026 03:00:00 CEST | Press release
Evosep and Mass Dynamics Join Forces to Standardize Proteomics Sample Preparation for Pharma
Oatly Group AB (publ)28.9.2026 22:05:00 CEST | Press release
Oatly to Report Third Quarter 2026 Financial Results on October 28, 2026
Teva Pharmaceutical Industries Ltd28.9.2026 22:00:00 CEST | Press release
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
Unlimit Group A/S28.9.2026 20:22:13 CEST | Pressemeddelelse
Unlimit Group A/S: Sikrer ny kapital og styrker balancen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
